Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Nanomedicine. 2018 Nov 22;18:414–425. doi: 10.1016/j.nano.2018.11.005

Figure 3. Size distributions of rGP ULV and ICMV formulations.

Figure 3.

(A) Table of intensity-based nanoparticle sizes, and polydispersity indices and zeta potentials from Zetasizer measurements, along with number-based nanoparticle diameters by nanoparticle tracking analysis. Measurements reported as mean ± standard deviation. (B) Intensity-based and (C) number-based size distributions of antigen-loaded ICMV formulations, compared with the respective ULVs.